The inherent or induced resistance of tumors to cytostatic agents is a major clinical problem.
In this review, we summarize the pre-clinical mechanisms of acquired and inherent …

Gemcitabine is a deoxycytidine (dCyd) analogue with activity against several solid cancers.
Gemcitabine is activated by dCyd kinase (dCK) and interferes, as its triphosphate dFdCTP …

Mechanisms of acquired resistance to three purine analogues, 2-chloro-2′-
deoxyadenosine (cladribine, CdA), 9-β-d-arabinofuranosyl-2-fluoroadenine (fludarabine …

Abstract 2′, 2′-Difluorodeoxycytidine (gemcitabine, dFdCyd) is a deoxycytidine analogue
with promising antitumor activity. In order to be active it must be phosphorylated by …

Gemcitabine (2′, 2′-difluoro 2′-deoxycytidine, dFdC) is the most important cytidine
analogue developed since cytosine arabinoside (Ara-C). The evidence of its potent …

Abstract Gemcitabine (2 I, 2 I-difluorodeoxycytidine, dFdC) is a nucleoside analogue of
deoxycytidine in which two fluorine atoms have been inserted into the deoxyribofuranosyl …

Summary Synopsis Gemcitabine [2′-deoxy-2′, 2′-difluorocytidine monohydrochloride (β
isomer); dFdC] is a novel deoxycytidine analogue which was originally investigated for its …

Deoxycytidine kinase (dCK) is essential for the phosphorylation of gemcitabine (2′, 2′-
difluorodeoxycytidine), a deoxycytidine analogue active against various solid tumors …

Gemcitabine is the first-line treatment for pancreatic ductual adenocarcinoma (PDAC) as
well as acts against a wide range of other solid tumors. Patients usually have a good initial …

Gemcitabine (dFdC, 2', 2'-difluorodeoxycytidine) is a deoxycytidine nucleoside analogue of
deoxycytidine in which two fluorine atoms have been inserted into the deoxyribose ring. Like …